Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Blin

Showing results (31-40 of 95) with videos related to

Pageof 10
Sort By:
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 30, 2019
Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDSPatrick Blin, Caroline Dureau-Pournin, Jacques Bénichou, et al.
British Journal of Clinical Pharmacology|March 28, 2017
Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims databasePatrick Blin, Caroline Dureau-Pournin, Régis Lassalle, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 21, 2021
Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDSPatrick Blin, Caroline Dureau-Pournin, Jacques Bénichou, et al.
World Journal of Urology|June 10, 2025
Comparative effectiveness of robot-assisted vs. open prostatectomy: a real-life nationwide studyGrégoire Robert, Patrick Blin, Franck Bladou, et al.
Pharmacoepidemiology and Drug Safety|March 26, 2024
Design and validation of algorithms to identify venous thromboembolism in the French National Healthcare DatabaseNicolas H Thurin, Angela Grelaud, Adeline Grolleau, et al.
British Journal of Clinical Pharmacology|November 14, 2018
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillationPatrick Blin, Caroline Dureau-Pournin, Yves Cottin, et al.
Clinical Pharmacology and Therapeutics|December 1, 2018
Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial FibrillationPatrick Blin, Caroline Dureau-Pournin, Yves Cottin, et al.
Pharmacoepidemiology and Drug Safety|November 9, 2022
High-dimensional propensity scores for empirical covariate selection in secondary database studies: Planning, implementation, and reportingJeremy A Rassen, Patrick Blin, Sebastian Kloss, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 23, 2026
Dual Antiplatelet Therapy beyond 1 Year after a Myocardial Infarction Compared with Low-Dose Aspirin Alone: A 3-Year Follow-Up Cohort Study Within the French SNDS Nationwide Claims DatabasePatrick Blin, Nicolas Danchin, Jacques Benichou, et al.
Epidemiology (Cambridge, Mass.)|October 1, 2013
Relative risks from case-population dataNicholas Moore, Sinem Ezgi Gulmez, Patrick Blin, et al.
Pageof 10

Showing results (31-40 of 95) with videos related to

Sort By:
Pageof 10
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 30, 2019
Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDSPatrick Blin, Caroline Dureau-Pournin, Jacques Bénichou, et al.
British Journal of Clinical Pharmacology|March 28, 2017
Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims databasePatrick Blin, Caroline Dureau-Pournin, Régis Lassalle, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 21, 2021
Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDSPatrick Blin, Caroline Dureau-Pournin, Jacques Bénichou, et al.
World Journal of Urology|June 10, 2025
Comparative effectiveness of robot-assisted vs. open prostatectomy: a real-life nationwide studyGrégoire Robert, Patrick Blin, Franck Bladou, et al.
Pharmacoepidemiology and Drug Safety|March 26, 2024
Design and validation of algorithms to identify venous thromboembolism in the French National Healthcare DatabaseNicolas H Thurin, Angela Grelaud, Adeline Grolleau, et al.
British Journal of Clinical Pharmacology|November 14, 2018
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillationPatrick Blin, Caroline Dureau-Pournin, Yves Cottin, et al.
Clinical Pharmacology and Therapeutics|December 1, 2018
Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial FibrillationPatrick Blin, Caroline Dureau-Pournin, Yves Cottin, et al.
Pharmacoepidemiology and Drug Safety|November 9, 2022
High-dimensional propensity scores for empirical covariate selection in secondary database studies: Planning, implementation, and reportingJeremy A Rassen, Patrick Blin, Sebastian Kloss, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 23, 2026
Dual Antiplatelet Therapy beyond 1 Year after a Myocardial Infarction Compared with Low-Dose Aspirin Alone: A 3-Year Follow-Up Cohort Study Within the French SNDS Nationwide Claims DatabasePatrick Blin, Nicolas Danchin, Jacques Benichou, et al.
Epidemiology (Cambridge, Mass.)|October 1, 2013
Relative risks from case-population dataNicholas Moore, Sinem Ezgi Gulmez, Patrick Blin, et al.
Pageof 10